Introduction Diabetes mellitus is a major chronic disease burden and is the underlying aetiology for the majority of mortality and morbidity such as renal failure and amputation. Many organizations including the World Health Organization have issued diagnostic criteria for diabetes based on four abnormalities, which include fasting glucose, random glucose with symptoms, oral glucose tolerance test and haemoglobin A 1c . The main focus of diabetic management continues to be glycaemic control as determined by haemoglobin A 1c levels as well as by a new marker, GlycoMark
Introduction
Diabetes mellitus is the sixth leading cause of death in the United States. It is the leading cause of end-stage renal disease as well as the reason for new cases of blindness and amputation. The Centre of Disease Control estimated that in 2010, there were nearly 26 million Americans (11.3% of adults) with diabetes and nearly 80 million Americans with pre-diabetes. The number of Americans affected by this chronic condition continues to grow. If these numbers remain on the current trajectory, it is estimated that one in three Americans will have diabetes by 2050 1 . The traditional pathophysiology model for this condition is represented by a triad of malfunctions including impaired insulin secretion, increased hepatogluconesis production and decreased glucose uptake. However, more recent data suggest a multifactorial malfunction. In addition to the previous triad, there is a decrease of incretin effect, increased glucagon secretion from islet cells, neurotransmitter dysfunction, increased glucose reabsorption and increased lipolysis. The underlying aetiology of these malfunctions is inflammation, with NF-kB as the leading cytokines. These inflammatory cascades will lead to β-cell destruction as well as to a decrease in their mass.
By the time a patient reaches the stage of pre-diabetes, as many as 40% of the β-cells are lost. With the diagnosis of overt diabetes, approximately 50%-60% of the β-cells are lost. The initiation of insulin for the management of diabetes is often reserved for cases where oral agents have failed or are inadequately controlling the hyperglycaemia. However, by this time, as many as 70%-80% of the β-cells are lost. In addition to the destruction of the β-cells, there is a reduction in the mass of the β-cells, which translates to a decrease in function. Therefore, the remaining β-cells produce much less insulin 2 . In this review, the methods to manage different types of diabetes mellitus are discussed.
Discussion

Evaluations and diagnosis
For being diagnosed with diabetes mellitus, a patient must have one of the following criteria: (1) fasting glucose levels greater than 126 mg/dl (fasting is defined as no caloric intake for at least 8 h), (2) random plasma glucose levels greater than 200 mg/dl with classic symptoms (polyuria, polydipsia and unexplained weight loss), (3) oral glucose tolerance test (OGTT) values greater than 200 mg/dl and (4) serum A 1c levels greater than 6.5%. Ideally, each of the tests should be carried out twice for confirmation of the results. The standardized 75-g 2-h OGTT (fasting glucose, repeated 2 h later) is strongly recommended. In addition, the patient needs to be fasting for 10-16 h and on a high high mortality of diabetes, higher glucose variability has a major influence on mortality and morbidity. In other words, it is better to have higher HbA 1c or glycaemic levels with a smaller range between the low and high levels than it is to have lower HbA 1c with larger differences between the high and low levels. One way to determine glucose variability is to increase the frequency of glucose self-monitoring, which is not always practical for patients. A better way to account for glucose variability is continuous glucose monitoring (discussed in later sections).
Lifestyle changes
The first-line therapy for all diabetes mellitus regardless of the type and severity includes lifestyle changes such as exercise and proper diet. It is recommended to have a prescription for exercise that consists of moderate intensity for a total of 150 min a week (averages to be 30 min/day for 5 days/week). Moderate intensity is defined as any activity that will elevate the patient's pulse by 50%-70% from its baseline rate or 40%-60% of VO 2max
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. Diet modifications include a decrease in the reduction of carbohydrates and an increase in green leafy vegetables, such as spinach, kale and lettuce 9 . (Table 1 ). In addition to glycaemic control, the other crucial aspect of preventing diabetic complications is controlling the glucose variability 7 . Although hypoglycaemia is a major factor in the carbohydrate diet for 3 days before the test. Therefore, the other three criteria are more often used.
In recent years, national guidelines from the American Diabetes Association (ADA) and American Academy of Clinical Endocrinologist (AACE) have allowed for the use of haemoglobin A 1c (HbA 1c ). Previously, the use of HbA 1c was not recommended for the diagnosis of diabetes due to large variations in laboratory results. However, more of the point-ofcare equipment for HbA 1c has been standardized. Therefore, when using HbA 1c to diagnose diabetes mellitus, it is critical to use the equipment that has been standardized by the National Glycohemglobin Standardization Program. The ADA states that an HbA 1c level between 5.7% and 6.4% is pre-diabetes while the AACE states the range as 5.5%-6.4%. Other considerations when using HbA 1c include misleading results in certain hematologic conditions such as anaemias, haemoglobinopathies, renal failure, dialysis and erythropoietin therapy.
To differentiate type 1 diabetes from type 2, C-peptide and auto-antibodies should be used. C-peptide is a by-product of insulin production. Since type 1 diabetes does not produce insulin, C-peptide levels are absent. In addition to the C-peptide's negative result, two or more positive tests for the auto-antibodies will confirm the diagnosis of type 1 diabetes. Auto-antibodies include antiglutamic acid decarboxylase, islet cell antibody, insulin antibody, islet antigen-2 or islet cell antibodies and zinc transporter 8. Once type 1 diabetes has been diagnosed, patients should be examined for thyroid problems, B12 deficiency celiac disease as well as other autoimmune disorders.
Management
Understanding HbA 1c and glycaemic control One of the key points in the management of diabetes mellitus is to prevent diabetic complications. To 
Oral agents
Most of the time, changes in lifestyle alone will not be adequate to achieve glycaemic control. Often, it is necessary to add pharmacological agents. There are various options for pharmacological therapies (Table 2) . Among the nine classes of oral diabetic medications, the insulin secretagogues include the sulphonylureas, meglitinides and dipeptidyl peptidase-4 (DPP-4). This class of drugs works on the pancreas to increase the production of insulin. Sulphonylureas are one of the oldest classes of diabetes medication; therefore, these drugs are inexpensive but they have a high risk of hypoglycaemia and increased weight gain. The older generation drugs such as glyburide have a higher risk of hypoglycaemia compared with the newer generation drugs such as glipizide. Like the sulphonylureas, the meglitinides also have an increased risk of hypoglycaemia and weight gain. Both these classes have a rapid response to lower blood sugar. The DPP-4 such as sitagliptin is not only weight neutral and may help with weight loss but it may help preserve β-cells. The two insulin sensitizers include the thiazolidinedione (TZD) and biguanide. The TZD class only has two medications -rosiglitazone and pioglitazone. In recent years, TZD has been linked to increase the risk of heart disease especially rosiglitazone. Currently, the FDA has placed rosiglitazone into a special prescribing category. The drug classes that affect gastrointestinal absorption and motility are the alpha-glucosidase inhibitor and bile sequestration (Colesevelam).
Once the diagnosis of diabetes mellitus type 1 is made, it is necessary to initiate insulin immediately. For type 2 diabetes, the first-line therapy can start with oral agents. For type 2 diabetes, the preferred first-line medication is metformin 10 . If glycaemic control is not achieved with metformin and lifestyle changes, then secretagogue or oral agents (such as . If two oral agents do not reach the limit for HbA 1c , then insulin needs to be considered. There are patients who will not consent to injections. Therefore, for this population, a third oral agent is reasonable. Another approach other than the secretagogue if metformin does not achieve glycaemic control is a glucagon-like peptide (GLP-1) agonist and TZD. As mentioned earlier, if HbA 1c does not reach a goal level after adding these agents, therapy must include insulin. When HbA 1c level is greater than 8.0%, dual therapy is considered initially.
Insulin
Insulin is divided into two board categories (human-based and synthetic or analog). Although there is slightly more variability than analog insulin, human insulin, including regular and neutral protamine Hagedorn (NPH) insulin, has similar hypoglycaemia and HbA 1c reduction as analog insulin (aspart, lispro, glulisine as well as glargine). Only the human-based insulin is generics. A more common classification of insulin includes dividing insulin into short acting, intermediate acting and long acting. Table 3 has a complete list of insulin and its pharmacokinetics.
Although not yet approved in the United States, degludec is approved in Europe and is being considered by FDA. Degludec is an ultra-long-acting insulin that requires patients to take insulin only three times a week. It has similar HbA 1c reduction properties and reduced hypoglycaemia compared with glargine 12, 13 . There are numerous approaches to initiate patients on insulin. Regardless of the approach, insulin therapy should be initiated sooner rather than later. This will allow some β-cells to recover while the body is getting its required insulin exogenously. This period is often referred to as a 'honeymoon' 14 . As mentioned earlier, many providers often delay insulin initiation, resulting in the ultimate destruction of as many as 70% of the β-cells.
There are various regimens including basal insulin alone, bolus alone, basal-bolus, premixed insulin and a combination thereof 15 . However, the most straightforward approach for initiating insulin is basal alone. This approach starts with the administration of a long-acting insulin (such as glargine) at bedtime. This starts with 10 units of insulin and then fasting morning glucose is checked every 2-3 days. If the value is above 130 mg/dl, then the dose is increased by 2-3 units every 2-3 days. When the fasting glucose is between 70 and 90-100 mg/dl, then the patient can remain on the current dosage. However, if the patient experiences hypoglycaemia (<70 mg/dl), then the long-acting insulin dose is decreased by 2-3 units or 10% if the dose is greater than 60 units. NPH insulin can be used as well. However, due to its half-life, it is generally dosed twice a day. This approach is often called the '303' (increased by 3 units, 0 units and decrease 3 units). For '202' protocol, the does is increased by 2 units, 0 units and decrease by 2 units. Once the patient is comfortable with the injections and/or the fasting glucose is under control, the preprandial insulin (basal-bolus) is introduced.
Another approach for insulin initiation is weight based. The daily total insulin is based on 0.1-0.2 units/ kg/day. This will be the starting dose of the long-acting insulin. Once this initial dosage is calculated, the insulin is adjusted every 2-3 days as described earlier. For more ambitious and technical patients who are willing to do multiple insulin injections to employ the basal-bolus regimen, the body's total daily insulin can be calculated by multiplying 0.5-1.5 units/kg/day. Then this total daily insulin is divided into half for basal and the other half for preprandial insulin. The half for preprandial insulin still needs to be divided further by three to cover breakfast, lunch and dinner 16 .
Other injectables
In the past couple of years, the GLP-1 has gained popularity in the diabetic world. It is an incretin that affects multiple organs (such as the brain, intestine, stomach, liver and pancreas) including preserving β-cells and its function. One of the most attractive attributes of this class is the weight loss. Exenatide (Byetta) was the first to be on the market. Liraglutide (Victoza) was FDA approved in 2010 and it is a longer-acting GLP-1 17 . Then the company of exenatide came out with a once-a-week injection (Bydureon) 18, 19 . The biggest side effect of this class of medication is nausea. With its weight loss property and its other beneficial effects, many endocrinologists are considering this class as first-line therapy or using this injectable before insulin 20 . Another incretin is pramlintide, which is an amylin-like protein.
Symlin is the only medication in this class. It came to the market several years before the GLP-1. It inhibits glucagon production in a glucosedependent mode and slows gastric emptying. However, it has no effect on β-cells like the GLP-1. Its use is a little more complicated since the units need to be converted to micrograms. In addition to the side effects of the nausea, it can have severe hypoglycaemia (which is not a problem with the GLP-1). Probably for these reasons, it did not become as popular as the GLP-1.
Difficult-to-manage diabetics
There are several types of patients who find it very difficult to obtain glycaemic control. One type has very volatile blood sugar levels swinging from the very high to the very low with only a slight adjustment to their insulin protocol. This is more common among type 1 diabetics. For these patients, the most appropriate treatment modality is an insulin pump. In recent years, there have been several brands of insulin pumps released on the market. Insulin available in the market. This type of insulin is about five times more potent than U-100 insulin. To calculate the dosage of the U-500 insulin, the total daily requirement of insulin is first calculated and the total daily requirement is divided by 5, which gives the total daily dosage for U-500 insulin. This type of insulin generally is given TID-QID; therefore the total daily requirement is divided into 3-4 dosages.
Conclusion
Even though insulin pumps are generally reserved for type 1 diabetes, they can be used for these highly insulin-resistant patients. When using insulin pumps for these patients, either U-100 or U-500 insulin can be used. Of course, the basal and bolus rate needs to be adjusted accordingly. Another consideration is the use of continuous glucose monitoring. These devices are similar to the insulin pump, which is attached to the body for 3-7 days and will check the subcutaneous glucose continuously (every 3-5 min) for 3-7 days. When the readings for these machines are downloaded, the glycaemic variability of the individual patients can be seen. These patterns can be used to custom cater the insulin regimen for the patients.
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Another approach is the combination of insulin and oral agents to help reduce the requirement of insulin. The use of metformin and/or TZD such as pioglitazone can increase peripheral tissue sensitivity to insulin. Other oral agents, which can be combined with insulin, include DPP-4 such as Januvia and bile acid sequestration such as Colesevelam. Even though insulin can be combined with secretagogues such as sulphonylurea, there is a high likelihood of hypoglycaemia especially in the elders. Therefore, extreme caution is required with this combination. Even though it is not FDA approved, GLP-1 and/or amylin injectables can be combined with insulin to help achieve the glycaemic control.
All the regimens of the various types of insulin mentioned earlier are classified as U-100 insulin. Currently, there is only one U-500 insulin
